Release date: 10 July 2019
Promoter – Financial Intermediary
ISA PHARMACEUTICALS BVLocation
Description
The project supports the company's research and development investments to complete the late stage development (clinical, regulatory, and manufacturing) of ISA101b - a synthetic long peptide (SLP) targeting human papilloma viruses (HPV) - in two HPV-induced therapeutic areas i.e. cervical, head and neck cancer.
Objectives
The proceeds from the EIB loan will be used to co-finance the project, which - if successful - will create new treatment options for patients suffering from these diseases, thereby addressing a substantial unmet medical need, and saving and improving the lives of thousands of patients. The project will also contribute to the growth of a European biopharmaceutical company and the creation of new high-skilled jobs.
Sector(s)
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 20 million
Total cost (Approximate amount)
EUR 48 million
Environmental aspects
The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under Directive 2014/52/EU amending the Directive 2011/92/EC. However, full environmental details verified during the appraisal are aligned with best practices.
Procurement
The promoter has been assessed by the EIB as being a private company not being subject to EU rules on public procurement or concessions.
Status
Signed - 28/06/2019
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).